e-SQUARE

healthcare online

                                 Vol. 1, No. 26, April 10, 2003

 

Caffeine & BP

New Gene!

Brain Infarcts & Dementia

Heart Problems Marker!

New Vaccine!

 Nutrient & Malaria

New Products

SARS update

SARS has killed at least 104 people and infected more than 2,600 worldwide.

Editorial Team

Omar Akramur Rab, MBBS, FCGP, FIAGP, FRSH (UK) 
Latifa Nishat, MBBS
  Shaokat Zaman, MBBS
Abdur Rahman, BBA
Thwe Thwe Prue, 

Web Developer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Editorial

 e- SQUARE- Readers' Choice       

 

Dear Doctor:

Hope you are enjoying "e-SQUARE". In this issue we are focusing on Caffeine & BP, New Gene!, Brain infracts & Dementia, Heart Problems Marker!, New Vaccine!, Nutrient & Malaria.

Please send your feedback on our information service to you. Click on to your reply mode.

Wish you all a happy, healthy and prosperous life.

Yours sincerely,

Editorial Team

 Reply Mode : e-square@squaregroup.com 

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE PHARMACEUTICALS LTD.

 

 

Caffeine & BP

Caffeine's effect on blood pressure                                                             Back to Feature

The caffeine may cause a jump in blood pressure - a particular problem in people who already have high blood pressure. In the study, caffeine quickly increased the stiffness of the large arteries in people with high blood pressure. Researchers tested the effects of caffeine on the major arteries of 10 people who were being treated for high blood pressure and were an average of 62 years old. On alternate days, the participants were given either a pill containing 250 mg of caffeine (the equivalent of 2-3 cups of coffee) or a placebo. Thirty minutes after the caffeine was given there was a big jump in the stiffness of their arteries. The effect peaked after 60 minutes and remained significant for at least three hours. This led to an 11-point jump in systolic blood pressure and an 8-point jump in diastolic blood pressure. Researchers say this finding is only preliminary and more research is needed to determine exactly how caffeine intake may influence blood pressure as well as determine who's at risk.

Source: WebMD

 

New Gene!

New breast cancer gene                                                       Back to Features

Science have discovered a new gene that is expressed at abnormally high levels in nearly 50% of the breast cancer specimens they examined and similarly over expressed in a large proportion of lung cancers (35%). The discovery of the gene, called KCNK9, is significant for several reasons. 

1.      KCNK9 reveals a previously unrecognized mechanism for oncogene action (namely, potassium channels).

2.      KCNK9 is an attractive target for the development of novel cancer therapies.

3.      The experimental overproduction of KCNK9 promotes tumor formation in controlled functional tests. This finding supports the notion that the over expression of KCNK9 observed in breast and lung tumor biopsies plays a bona fide role in these cancers. 

The study is also significant because it focused on sporadic or non-heritable forms of breast cancer. Sporadic disease accounts for greater than 90% of all breast and other cancers in contrast to heritable forms of cancer, which account for a relatively small percentage of the disease.

Source: Eureka Alert 2003

 

Brain Infarcts & Dementia

Silent brain infarcts linked to dementia                                 Back to Features

A new study shows people who suffer so called "silent" brain infarcts have more than double the risk of developing dementia. Researchers believe it will eventually impact one in four 55 year olds and the risk is expected to increase as life expectancy rises. Studies show vascular problems such as stroke play a role in the development of dementia and doctors have suspected minor, or "silent" strokes also put people at increased risk. Since these silent events appear on MRIs, these researchers studied a large group of people ages 60 to 90 to determine how silent infarcts impact memory and ability over time. Researchers found those with evidence of silent brain infarcts on their first MRI were twice as likely as those without such evidence to develop signs of dementia during the follow up. Subjects who demonstrated additional silent infarcts at the second MRI were more likely to show an increasing decline in cognitive function. Researchers believe the presence of silent infarcts on MRIs can be used to help identify people at increased risk for dementia.

Source : New England Journal of Medicine, 2003;348:1215-1220  

 

Heart Problems Marker!

Marker for acute heart problems                                          Back to Features 

A new marker, called soluble CD40 ligand, helps identify patients who are at high risk for cardiac events. Acute heart attack is commonly diagnosed by measuring markers for cardiac cellular death. These markers fail to give additional information about coronary artery plaque disruption or platelet activation, a central event in the formation of thrombus, which causes most unstable coronary syndromes. Markers for platelet activation could be used to identify disease activity before cardiac cell death occurs, thereby allowing physicians to better plan diagnostic procedures and therapy before a heart attack occurs. CD40 ligand is a protein important in the inflammatory processes that lead to thrombus formation and atherosclerosis, which occurs when the coronary arteries become narrow due to arterial plaques forming on the vessel lining. The authors found elevated levels of soluble CD40 ligand identify patients with an increased risk of thrombosis. These patients were effectively protected from cardiac events by administering therapy when compared to a control group.

Source: New England Journal of Medicine, 2003;348:1104-1109    

 

New Vaccine!

 "Meningitis A" vaccine hope                                      Back to Features

Scientists plan to start clinical trials of their vaccine within the next year. Meningitis is one of the world's most dreaded infectious diseases. Even with antibiotic treatment, at least 10% of patients die with another 10 to 20% left with permanent problems, such as mental retardation, deafness or epilepsy. Early tests suggest it can provide long lasting protection against the A strain of the disease. While a vaccine exists for this strain, it is not effective in young children - the group most at risk and only lasts for three years in adults. Clinical trials for the new  vaccine could start as early as 2004 and the new vaccine could be ready for wide use within the next four to five years.

Source: BBC health   

 

Nutrient & Malaria

 Nutrient prevent deadly malaria                                        Back to Feature

Researchers said a nutrient produced naturally in the body and found in some foods could be a potential new treatment for malaria. Researchers studied 75 children and discovered that those with the lowest levels of the nutrient arginine suffered the most severe effects of malaria. They believe that combining arginine, with anti-malaria drugs could be more effective way of combating the mosquito-borne diseases. Arginine may have potential as a complementary drug to augment existing anti-malaria drugs and to prevent complications from malaria. Arginine, an amino acid is found in nuts and rice. It boosts nitric oxide, a chemical that relaxes blood vessels and promotes blood flow by keeping arteries flexible and which can kill also parasites. The researchers believe higher levels of arginine and nitric oxide could increase blood flow and stop blood cells infected with the parasite from sticking to the lining of blood vessels.

  Source: Reuters Health 2003-02-21    

 

SQUARE Products introduced in 2003         Back to Features

Product                                    Vega 50 tab
Generic Name                      
   Rofecoxib
Strength                                 
50 mg
Dosage form                          
Tablet
Therapeutic Category          
Anti-rheumatic non steroidal         

Product                                    ARB 8
Generic Name                        
Candesartan
Strength                                  
8 mg
Dosage form                           
Tablet
Therapeutic Category           
Anti-hypertensive   

Product                                    Oxilar
Generic Name                    
    Raloxifene 
Strength                                 
60 mg
Dosage form                           
Tablet 
Therapeutic Category           
Bone calcium regulator

Back to Features                                                                                                   Continued...  

                               

 

We have sent this e-mail message to you in the belief that this service will be of interest. If you want to be removed from our mailing lists please send an e-mail to e-square@squaregroup.com quoting "unsubscribe" in the subject line.